Analysis of circulating tumor cells (CTCs) as a tool for monitoring metastatic cancers, early diagnosis, and evaluation of disease prognosis paves the way toward personalized cancer treatment.

The European Commission (EC) has granted conditional approval to Jazz Pharmaceuticals’ Ziihera (zanidatamab) to treat a ...

Jazz Pharmaceuticals (NASDAQ: JAZZ) is one of the best high short interest stocks with huge upside potential. On July 2, Jazz ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The EC granted conditional approval based on activity seen in a subset of IHC 3+ HER2-positive advanced biliary tract cancer patients in a Phase II trial.

The Human Epidermal Growth Factor Receptor 2 (HER2) is one of the aggressive subtypes of breast cancer. The HER2 status decides the requirement of breast cancer patients to receive HER2-targeted ...

Small-molecule irreversible tyrosine kinase inhibitors as high potent agents have led to improvements in disease-free and overall survival in patients with HER2-amplified cancer. The approved ...

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

The recent IMPACT-MBC study demonstrated a clear relationship between HER2 immunohistochemistry score and [89 Zr]Zr-trastuzumab PET SUV max, supporting the potential of molecular imaging to ...

Immunohistochemistry (IHC) analysis is the widely accepted method for molecular subtyping. It involves the assessment of the four molecular biomarkers namely estrogen receptor (ER), progesterone ...

cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing.